Biocept, Inc. (NASDAQ: BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. , according to the company’s website (see here: www.biocept.com). In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. via Skype, and they discuss the following topics:
- Overview of Biocept, Inc
- Highlights for 2019
- Recent financings and news in 2020
- How 2020 news affects the company going forward
- What to look out for in Q2 2020
For more information about Biocept, Inc., please visit: www.biocept.com
The interview may contain forward looking statements about Biocept, Inc. See Biocept’s periodic filings with the Securities and Exchange Commission for more complete information.
Please read our full disclosure here.